Literature DB >> 16900665

Acetylcholine receptors and tau phosphorylation.

A Rubio1, M Pérez, Jesús Avila.   

Abstract

Alzheimer's disease (AD) is characterized by the presence, in the brain of the patients, of two aberrant structures: intracellular neurofibrillary tangles (NFTs), containing an abnormal hyperphosphorylated form of tau protein, and extracellular senile plaques (SPs), mainly composed by fibrillar amyloid beta peptide. Another feature of AD is the neurodegeneration and dysfunction of basal forebrain cholinergic system. A possible connection among those AD characteristics could occur. Thus, the purpose of this short review is to summarize the involvement of nicotinic (nAChR) and muscarinic (mAChR) receptors on tau phosphorylation, in a direct way, or through the previous interaction of some of these receptors with amyloid beta. Several studies have demonstrated that nAChR activation results in a significantly increase of tau phosphorylation, whereas mAChR activation, may prevent tau phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16900665     DOI: 10.2174/156652406777435444

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  9 in total

Review 1.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

2.  Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study.

Authors:  Jennifer M Coughlin; Yuchuan Wang; Cynthia A Munro; Shuangchao Ma; Chen Yue; Shaojie Chen; Raag Airan; Pearl K Kim; Ashley V Adams; Cinthya Garcia; Cecilia Higgs; Haris I Sair; Akira Sawa; Gwenn Smith; Constantine G Lyketsos; Brian Caffo; Michael Kassiou; Tomas R Guilarte; Martin G Pomper
Journal:  Neurobiol Dis       Date:  2014-11-07       Impact factor: 5.996

3.  In vivo investigations on the cholinesterase-inhibiting effects of tricyclic quinazolinimines: scopolamine-induced cognitive impairments in rats are attenuated at low dosage and reinforced at higher dosage.

Authors:  D Appenroth; M Decker; C Tränkle; K Mohr; J Lehmann; C Fleck
Journal:  Pflugers Arch       Date:  2007-08-24       Impact factor: 3.657

Review 4.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 5.  Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.

Authors:  Concepcion Conejero-Goldberg; Peter Davies; Luis Ulloa
Journal:  Neurosci Biobehav Rev       Date:  2007-11-28       Impact factor: 8.989

6.  A Novel Ex Vivo Model to Investigate the Underlying Mechanisms in Alzheimer's Disease.

Authors:  Emanuele Brai; Skye Stuart; Antoine-Scott Badin; Susan A Greenfield
Journal:  Front Cell Neurosci       Date:  2017-09-20       Impact factor: 5.505

7.  Modulatory Effects of a Novel Cyclized Peptide in Reducing the Expression of Markers Linked to Alzheimer's Disease.

Authors:  Emanuele Brai; Florian Simon; Antonella Cogoni; Susan A Greenfield
Journal:  Front Neurosci       Date:  2018-06-13       Impact factor: 4.677

8.  Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.

Authors:  David L Sultzer; Aaron C Lim; Hailey L Gordon; Brandon C Yarns; Rebecca J Melrose
Journal:  Alzheimers Res Ther       Date:  2022-02-07       Impact factor: 8.823

9.  The effect of neostigmine on postoperative delirium after colon carcinoma surgery: a randomized, double-blind, controlled trial.

Authors:  Fanghao Liu; Xu Lin; Yanan Lin; Xiyuan Deng; Yuwei Guo; Bin Wang; Rui Dong; Yanlin Bi
Journal:  BMC Anesthesiol       Date:  2022-08-22       Impact factor: 2.376

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.